Janux Therapeutics (JANX) Liabilities and Shareholders Equity (2020 - 2026)

Janux Therapeutics (JANX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 2.15% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.1 billion (up 16.81% YoY), while the FY2025 annual figure was $1.0 billion, down 5.65% from the prior year.
• Liabilities and Shareholders Equity rose to $1.0 billion in Q1 2026 per JANX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q4 2024 and bottomed at $341.5 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $660.6 million across 5 years, with a median of $689.0 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity declined 11.38% — and 2024, when it soared 179.05%.
• Janux Therapeutics' Liabilities and Shareholders Equity stood at $364.0 million in 2022, then increased by 4.5% to $380.4 million in 2023, then jumped by 179.05% to $1.1 billion in 2024, then decreased by 5.65% to $1.0 billion in 2025, then gained by 2.66% to $1.0 billion in 2026.
• Business Quant data shows JANX's Liabilities and Shareholders Equity at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.